indazoles has been researched along with Benign Neoplasms in 274 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (4.38) | 18.7374 |
| 1990's | 14 (5.11) | 18.2507 |
| 2000's | 39 (14.23) | 29.6817 |
| 2010's | 164 (59.85) | 24.3611 |
| 2020's | 45 (16.42) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Fukami, TA; Hasegawa, K; Kim, SJ; Miura, T; Na, YJ; Ono, N; Shimma, N; Shindo, H; Shiratori, Y; Suda, A; Tsukuda, T; Yoon, DO | 1 |
| de Dios, A; Gelbert, LM; Lallena, MJ; Sánchez-Martínez, C | 1 |
| Araujo-Mino, E; Bardia, A; Dowlati, A; Drilon, A; Eshaghian, S; Gandara, DR; Gettinger, S; Goldberg, S; Hong, D; Kiedrowski, L; Lin, JJ; Liu, SV; McCoach, C; Mobayed, M; Morse, M; Nguyen, T; Nieva, JJ; Price, K; Rolfo, C; Russo, A; Sashital, D; Schram, AM; Stinchcombe, T; Subramanian, J; Vidula, N | 1 |
| Bonnefois, G; Buchheit, V; Djebli, N; Frey, N; González-Sales, M; Meneses-Lorente, G; Mercier, F; Tremblay, PO | 1 |
| Bennett, I; Krebs, MG | 1 |
| Hatswell, AJ; Sullivan, WG | 1 |
| Brose, MS; Carlson, JJ; Federman, N; Italiano, A; Kummar, S; Lassen, U; Sullivan, SD | 1 |
| Amani, AM; Dehaen, W; Ramezanpour, S; Shiri, P | 1 |
| Bessudo, A; Dezube, BJ; Duncan, M; Evilevitch, L; Gabrail, N; Guo, W; Hamilton, E; Kumar, S; Lu, S; Patel, MR; Rodon, J; Sachdev, J; Yap, TA | 1 |
| Barys, L; Beyer, KS; Bomio-Confaglia, C; Brachmann, SM; Burks, H; Chen, X; Cotesta, S; Cui, X; de Kanter, R; Dharmarajan, L; Farago, AF; Fedele, C; Gerspacher, M; Guthy, DA; Head, V; Jaeger, A; Kearns, JD; Leblanc, C; Lorthiois, E; Maira, SM; Murphy, J; Núñez, EJ; Oakman, H; Ostermann, N; Ottl, J; Rigollier, P; Roman, D; Schnell, C; Sedrani, R; Shimizu, T; Stringer, R; Vaupel, A; Voshol, H; Weiss, A; Wessels, P; Widmer, T; Wilcken, R; Xu, K; Zecri, F | 1 |
| Guria, T; Maity, A; Paul, A; Roy, P | 1 |
| Adachi, A; Darwis, NDM; Hirota, Y; Horigome, E; Li, S; Ohno, T; Oike, T; Shibata, A | 1 |
| Chen, D; Gu, Y; Kang, L; Liu, S; Liu, Y; Qiu, H; Yang, J; Zhao, H; Zhao, Y | 1 |
| Aoyama, M; Hirano, H; Ishikawa, K; Nemoto, S; Osada, H; Semba, K; Watanabe, N; Watanabe, S | 1 |
| Chen, SW; Mu, HX; Shi, JT; Wang, QS; Wang, S; Wang, XR; Wang, XT; Xu, KY | 1 |
| Huygens, S; Koleva-Kolarova, R; Nagy, B; Rutten-van Mölken, M; Szilberhorn, L; Vellekoop, H; Versteegh, M; Wordsworth, S; Zelei, T | 1 |
| Gou, S; Huang, X; Wang, H; Zhang, B | 1 |
| Berger, MF; Cocco, E; Cownie, J; de Stanchina, E; Drilon, A; Ebata, K; Guzman, S; Hechtman, JF; Houck-Loomis, B; Hyman, DM; Kulick, A; Ladanyi, M; Lanman, RB; Mattar, M; Misale, S; Nagy, RJ; Patel, JA; Ptashkin, R; Razavi, P; Samoila, A; Scaltriti, M; Schram, AM; Selçuklu, SD; Shifman, S; Somwar, R; Toska, E; Tuch, BB; Won, HH; Yaeger, R | 1 |
| Mullard, A | 1 |
| Drilon, A | 1 |
| Aschenbrenner, DS | 1 |
| Liu, J; Tang, X; Wu, C; Xu, K; Zhai, Z; Zhong, W | 1 |
| Lassen, U | 1 |
| Jørgensen, JT | 1 |
| Barve, M; Bazhenova, L; Besse, B; Blakely, CM; Bowles, DW; Buchschacher, GL; Chae, YK; Chawla, SP; Cho, BC; Chow-Maneval, E; Conkling, P; Cui, N; Demetri, GD; Doebele, RC; Drilon, A; Eng, S; Fakih, M; Farago, AF; Fox, E; Garrido, P; Garrido-Laguna, I; John, T; Johnson, A; Krauss, JC; Liu, SV; Loong, HH; Nieva, J; Overbeck, TR; Paz-Ares, L; Riehl, T; Seto, T; Shaw, AT; Siena, S; Sigal, D; Simmons, B; Steuer, C; Tosi, D; Wilson, TR | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
| Al-Lazikani, B; Ameratunga, M; Antolin, AA; Banerji, U; Clarke, PA; Workman, P | 1 |
| Broaddus, R; Fu, S; Hess, K; Hong, D; Janku, F; Karp, D; Kopetz, S; Liu, L; Naing, A; Overman, M; Piha-Paul, S; Shi, N; Subbiah, V; Tsimberidou, AM; Wang, Y; Yao, J | 1 |
| Bailey, JJ; Jaworski, C; Schirrmacher, R; Tung, D; Wängler, B; Wängler, C | 1 |
| Barbacid, M | 1 |
| Aoki, M; Harada, T; Hirose, K; Ichise, K; Kato, T; Sato, M; Takai, Y; Takeda, K; Wada, Y | 1 |
| Battistone, B; Garrido-Laguna, I; Ghazi, P; Kinsey, CG; McMahon, M; Parkman, GL; Scherzer, MT; Schuman, S; Truong, A; Vaishnavi, A | 1 |
| Baltas, M; Eddahmi, M; El Ammari, L; Gangemi, R; Kandri Rodi, Y; Kouakou, A; Laghchioua, FE; Maric, I; Monticone, M; Rakib, EM; Saadi, M; Viale, M | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Ardini, E; Siena, S | 1 |
| Walker, A | 1 |
| Aungst, S; Donoghue, M; Helms, WS; Keegan, P; Marcus, L; Myers, CE; Pazdur, R; Shen, G; Stephens, O; Zhao, H | 1 |
| Delaye, M; Rodrigues, M | 1 |
| Bang, YJ; Bendell, J; Carlsen, M; Chow, KH; Chung, HC; de Miguel, MJ; Gandhi, L; Italiano, A; Lin, CC; Patnaik, A; Schmidt, S; Su, WC; Szpurka, AM; Vangerow, B; Xu, X; Yap, TA; Yu, D; Zhao, Y | 1 |
| Cui, G; Hou, Y; Meng, T; Shang, C; Shi, M | 1 |
| Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G | 1 |
| Lassen, U; Rohrberg, KS | 1 |
| Bentley, D; Brink, A; Buchheit, V; Chow-Maneval, E; Djebli, N; Guerini, E; Kowalski, K; Meneses-Lorente, G; Mercier, F; Phipps, A; Yu, L | 1 |
| Álvarez, R; Bautista, F; Colomer, R; de Álava, E; Garrido, P; Hladun, R; López-Ríos, F; Rojo, F | 1 |
| Iwasa, S; Kase, Y; Kitano, S; Kondo, S; Koyama, T; Sato, J; Shibaki, R; Shimizu, T; Shimomura, A; Sumino, S; Suri, A; Tamura, K; Yamamoto, N; Yonemori, K | 1 |
| Balardy, L; Cabarrou, B; Chatelut, E; Digue, L; Filleron, T; Gomez-Roca, CA; Le Louedec, F; Mourey, L; Olivier, P; Paludetto, MN; Ravaud, A; Valentin, T | 1 |
| Anandappa, G; Boink, Y; Bond, SJ; Brune, C; Cheriyan, J; Gajendragadkar, P; Hubsch, A; Jodrell, DI; Mäki-Petäjä, KM; McEniery, CM; McGeoch, A; Meyer, PAR; Mir, F; Ramenatte, N; Santos Franco, S; Schönlieb, CB; Wilkinson, IB; Yang, LL | 1 |
| Bui, NQ; Chawla, N; Seetharam, M | 1 |
| Khan, T; Prabhu, A; Sankhe, K | 1 |
| Guo, Q; Liu, L; Lu, W; Ma, Z; Sun, X; Wang, S; You, J; Zhang, Y; Zhao, Z | 1 |
| Argyle, D; Bradley, M; Dong, H; Gao, Q; Geng, J; Neumann, K; Porter, H; Potter, M; Ren, H; Zhang, Y | 1 |
| Bottaro, DP; Cecchi, F; Chen, AP; Do, KT; Doroshow, JH; Jeong, W; Johnson, BC; Kummar, S; Lee, YH; Navas, T; Parchment, RE; Park, SR; Rubinstein, L; Srivastava, AK; Voth, AR; Wright, JJ | 1 |
| Chen, B; Kankala, RK; Krastev, R; Li, X; Liu, Y; Long, R; Wang, P; Wang, S; Xiong, X; Yang, D; Zhang, Y; Zhu, M | 1 |
| Cai, Z; Cao, D; Chang, C; Jiang, Z; Liu, C; Mu, M; Shen, C; Yin, X; Yin, Y; Zhang, B; Zhang, L; Zhao, Z | 1 |
| Cheng, HJ; Chu, YY; Li, G; Li, WB; Sun, CJ; Tian, ZH; Zhao, JC | 1 |
| Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML | 1 |
| Chen, H; Hao, K; Liu, J; Liu, W; Wang, G; Wang, W; Yan, F; Zhang, J; Zhou, F | 1 |
| Aguirre, A; Cabrera, AR; Daniliuc, CG; Espinosa-Bustos, C; Faúndez, M; Jaque, P; Meléndez, J; Rojas, RS; Salas, CO | 1 |
| Altman, RB; Klein, TE; Sharma, MR; Thorn, CF | 1 |
| Gu, J; Li, J | 1 |
| Bowles, DW; Lackner, MR; Leong, S; Moss, RA; Schellens, JHM; Schutzman, JL; Shankar, G; Spoerke, JM; van der Noll, R; Voest, EE; Ware, JA; Zhou, J | 1 |
| Bhamra, A; Broncel, M; Huang, PH; McCarthy, F; Paul, A; Vyse, S; Wong, JP | 1 |
| Angapelly, S; Angeli, A; Arifuddin, M; Sri Ramya, PV; Supuran, CT | 1 |
| Beckedorff, F; Lai, F; Pastori, C; Shiekhattar, R; Yue, J; Zhang, A | 1 |
| Alessi, DR; Arkin, MR; Bainbridge, TW; Beresini, MH; Blackwood, E; Blake, RA; Brasher, B; Chang, MT; Clark, KR; Cohen, F; Di Lello, P; Drummond, J; Ernst, JA; Forrest, WF; Gnad, F; Hearn, BR; Heideker, J; Jaishankar, P; Kategaya, L; Kleinheinz, T; Klijn, C; Kwok, MCM; Lin, E; Ma, TP; Martin, SE; Maurer, T; McCleland, M; Murray, J; Ndubaku, C; Pastor, R; Peale, F; Prakash, S; Renslo, AR; Ritorto, MS; Rougé, L; Schwerdtfeger, C; Stiffler, Z; Tang, Y; Trost, M; Tsui, V; Upton, JP; Wang, X; Wertz, IE; Yu, K | 1 |
| Chellappan, DK; Chellian, J; Foo, JH; Gupta, G; Hang, LY; Ling, J; Nathan, S; Ng, ZY; Sim, YJ; Singh, Y; Theng, CW; Wong, M; Yang, GJ | 1 |
| Albiol-Chiva, J; Esteve-Romero, J; Peris-Vicente, J | 1 |
| Alessio, E; Messori, L | 1 |
| Adjei, AA; Bishop, WR; Carr, D; Chun, P; Cooper, A; Dayananth, P; Deng, Y; Flaherty, KT; Fong, PC; Hwu, WJ; Kirschmeier, P; Long, BJ; Miselis, NR; Moreno, BH; Moschos, SJ; Ramanathan, RK; Ribas, A; Robert, L; Rubin, EH; Rubino, J; Rush, TS; Samatar, AA; Schiller, J; Shapira-Frommer, R; Shipps, GW; Sullivan, RJ; Tawbi, HA; Zhang, D | 1 |
| Arsenian-Henriksson, M; Bhatia, R; Campbell, J; Carmena, M; Chu, S; D'Hollander, ACA; Darekar, S; Drummond, CJ; Earnshaw, WC; Fandalyuk, Z; Färnegårdh, K; Franco, M; Gelebart, P; Gustavsson, AL; Håkansson, M; Haraldsson, M; Healy, AR; Higgins, M; Johansson, L; Ladds, MJGW; Laín, S; Lane, DP; Larsson, K; Lunec, J; McCarthy, AR; McCormack, E; Mollick, T; Nekulova, M; Pastor Fernández, A; Peat, EM; Pelechano, V; Popa, M; Popova, G; Sachweh, MCC; Safont, MM; Saleh, A; Sedimbi, SK; Svensson, R; Thompson, AM; Tuck, C; van Leeuwen, IMM; Vojtesek, B; Walse, B; Westwood, NJ; Yngve, U; Zhao, Y | 1 |
| Beijnen, JH; Groenland, SL; Herbrink, M; Huitema, ADR; Nuijen, B; Schellens, JHM; Steeghs, N | 1 |
| Hanashi, A; Ishikawa, A; Kakutani, S; Kinoshita, Y; Miyamoto, S; Sato, Y | 1 |
| He, S; Li, W; Tang, Z; Wan, Y | 1 |
| Bins, S; Bouazzaoui, SE; Gelderblom, H; Hamberg, P; Huitema, ADR; Koolen, SLW; Laven, P; Mathijssen, RHJ; Sleijfer, S; Steeghs, N; van Erp, N; van Herpen, C; van Schaik, RHN; Yu, H | 1 |
| Chen, J; Chen, Y; He, J; Huang, W; Li, Y; Liu, S; Njoya, EM; Qian, S; Wang, F; Wang, Z; Xie, C; Yang, L | 1 |
| Christian, S; Danciu, OC; Dudek, AZ; Fischer, JH; Liu, LC; Russell, MJ; Shah, HA; Venepalli, NK; Zacny, JP | 1 |
| Bendell, J; Chan, IT; Cleary, JM; de Crespigny, A; Fredrickson, J; Gates, MR; Hsieh, HJ; Jones, S; Kurkjian, C; Kwak, E; LoRusso, P; Musib, L; Pandya, S; Pilat, MJ; Rudin, CM; Shapiro, GI; Wongchenko, M; Yan, Y | 1 |
| Bedard, PL; Bray, MR; Brokx, R; Bruce, J; Cescon, DW; Denny, T; Fletcher, G; Li, SW; Mak, TW; Pugh, TJ; Sampson, P; Slamon, DJ; Veitch, ZW; Wainberg, ZA; Yonemoto, LM | 1 |
| Näär, AM; Wu, S | 1 |
| Ju, RJ; Li, N; Li, XY; Lu, WL; Ma, X; Wang, XX; Zhang, CX; Zhang, L; Zhao, WY; Zhou, J | 1 |
| Babur, M; Brown, G; Burrows, N; Cawthorne, C; Dive, C; Forster, D; Gieling, RG; Gregory, J; Hiscock, D; Hodgkinson, C; McMahon, A; Morrow, CJ; Radigois, M; Simpson, K; Smigova, A; Williams, KJ; Wilson, I | 1 |
| Choueiri, TK; Hapani, S; Kapadia, S; Wu, S | 1 |
| He, AN; Qi, WX; Shen, Z; Yao, Y | 1 |
| Fahldieck, C; Kalich, J; Lichtenfels, R; Riemann, D; Schulz, K; Seliger, B; Stehle, F | 1 |
| Botbyl, J; Edenfield, JW; Gibbon, DG; Gregory, C; Lindquist, D; Martin, JC; Stein, MN; Stephenson, JJ; Suttle, AB; Tada, H; Tan, AR | 1 |
| Belani, CP; Chung, V; Dowlati, A; Gandhi, L; Hamilton, AL; Harvey, RD; Ivy, SP; Kummar, S; Lau, SC; Lenz, HJ; Longmate, JA; LoRusso, P; Mulkerin, DL; Newman, EM; O'Neil, BH; Ottesen, LH; Rudek, MA; Sarantopoulos, J; Shibata, SI; Suttle, AB; Synold, TW | 1 |
| Chen, Y; Garrett, M; Hee, B; Klamerus, KJ; Pithavala, YK; Tortorici, MA | 1 |
| Christensen, S; Dutia, MP; Eddings, C; Lara, PN; Semrad, TJ | 1 |
| Gao, M; Miller, KD; Wang, M; Zheng, QH | 1 |
| Baird, RD; Carpenter, CL; Chatterjee, M; de Bono, JS; Forster, M; Gevensleben, H; Hylands, L; Iannone, R; Kaye, SB; Kreischer, N; Loughney, J; Miranda, S; Moreno, V; Omlin, A; Riisnaes, R; Sandhu, SK; Schelman, WR; Sun, L; Thway, K; Toniatti, C; Wenham, RM; Wilding, G | 1 |
| Burris, HA; Infante, JR | 1 |
| Nissan, MH; Rosen, N; Solit, DB | 1 |
| Ahern, CH; Baruchel, S; Blaney, SM; Glade Bender, JL; Harris, P; Ingle, AM; Lee, A; Reid, JM; Roberts, T; Voss, SD; Weigel, BJ; Wu, B | 1 |
| Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE | 1 |
| Carlson, DM; Chiu, YL; Pradhan, RS; Ricker, JL | 1 |
| Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Awni, W; Carlson, DM; Chiu, YL; Hosmane, B; Lorusso, P; Ricker, JL | 1 |
| Carlson, D; Koenig, D; Salem, AH | 1 |
| Boers-Sonderen, MJ; de Bruijn, P; Eskens, FA; Hamberg, P; Sleijfer, S; Suttle, AB; van der Graaf, WT; van Herpen, CM; Verweij, J | 1 |
| Ando, Y; Araki, K; Inada-Inoue, M; Ishida, H; Kawada, K; Mitsuma, A; Mizuno, K; Nagamatsu, K; Nagashima, F; Sasaki, Y; Sawaki, M; Sunakawa, Y; Takekura, A; Yamashita, K; Yokoyama, T | 1 |
| Antonysamy, MA; Bliss, RL; Dudek, AZ; Fischer, JH; Ganesan, C; Jha, G; Obulareddy, SJ | 1 |
| Chiu, YL; LoRusso, P; Ricker, JL; Xiong, H | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B | 1 |
| Brown, P; Carducci, M; Hurwitz, H; Pili, R | 1 |
| Bauer, TM; Bendell, JC; Burris, HA; Hinson, JM; Infante, JR; Jones, S; Orlemans, EO; Ramanathan, RK; Tibes, R; Von Hoff, DD; Weiss, GJ | 1 |
| Cohen, EE; Fruehauf, JP; Garrett, M; Kim, S; Pithavala, YK; Ruiz-Garcia, A; Tortorici, MA | 1 |
| Ang, JE; Baird, R; Clarke, PA; de Bono, JS; Derynck, MK; Fredrickson, J; Friedman, LS; Kaye, SB; Kristeleit, R; Lackner, MR; Levy, G; Lin, R; Mazina, K; Moreno, V; Raynaud, FI; Sarker, D; Shah, K; Spoerke, JM; Ware, JA; Workman, P; Wu, J; Yan, Y | 1 |
| Compton, N; Kendra, KL; O'Brien, ME; Ottesen, LH; Paul, EM; Plummer, R; Salgia, R; Suttle, AB; Villalona-Calero, MA; Xu, CF | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB | 1 |
| de Bruijn, P; de Jonge, MJ; Eskens, FA; Hamberg, P; Leonowens, C; Mathijssen, RH; Sleijfer, S; van der Biessen, D; Verweij, J | 1 |
| Chen, Y; Garrett, M; LaBadie, RR; Pithavala, YK; Suzuki, A; Tortorici, MA; Umeyama, Y | 1 |
| Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R | 1 |
| Awrey, DE; Ban, F; Beletskaya, I; Cumming, G; Edwards, L; Feher, M; Forrest, B; Hodgson, R; Huang, P; Kiarash, R; Laufer, R; Li, SW; Liu, Y; Luo, X; Madeira, B; Mak, TW; Mao, G; Mason, JM; Nadeem, V; Pan, G; Patel, NK; Pauls, HW; Plotnikova, O; Sampson, PB; Wei, X | 1 |
| Berndsen, RH; Bonvin, D; Dyson, PJ; Griffioen, AW; Nowak-Sliwinska, P; Scherrer, E; Weiss, A; Wong, TJ | 1 |
| Jones, P; Rowley, M; Toniatti, C; Wilcoxen, K | 1 |
| Chen, M; Hu, Y; Liu, T; Ma, X; Song, P; Xu, L; Zhou, Y | 1 |
| Liu, HM; Qi, PP; Yu, B; Yu, DQ; Yu, Z | 1 |
| Booth, L; Cruz-Luna, T; Cycon, KA; Dent, P; Doern, CD; Fidanza, A; Nourbakhsh, A; Plamondon, P; Roberts, JL; Siembida, P; Smith, E; Tavallai, M | 1 |
| Bracarda, S; Carpenter, C; Chen, M; Compton, N; Harter, P; Heise, M; Hutson, T; Kaplowitz, N; Norry, E; Pandite, L; Powles, T | 1 |
| Bellido, J; Falchook, G; Fu, S; Hong, D; Janku, F; Karp, D; Ke, D; Kurzrock, R; Lim, J; Naing, A; Piha-Paul, S; Rodrigues, HV; Stephen, B; Subbiah, V; Tsimberidou, A; Wheler, J; Zinner, R | 1 |
| Briley, LP; du Bois, A; Johnson, T; Parham, LR; Russo, M; Song, K; Spraggs, CF; Tada, H; Xu, CF | 1 |
| Aversa, C; Geuna, E; Leone, F; Martinello, R; Milani, A; Montemurro, F; Serini, G; Valdembri, D; Zucchini, G | 1 |
| Bruce, JY; Carmichael, LL; Eickhoff, JC; Heideman, JL; Jeraj, R; Kolesar, JM; Liu, G; Perlman, SB; Scully, PC | 1 |
| Bordeleau, F; Han, S; Huang, FK; Huang, J; Huang, XY; Liu, B; Reinhart-King, CA; Xing, B; Zhang, JJ | 1 |
| Cervantes-Madrid, D; Dueñas-González, A | 1 |
| Fu, S; George, GC; Henary, H; Hong, DS; Kurzrock, R; Mistry, R; Naing, A; Piha-Paul, S; Wheler, J; Zinner, R | 1 |
| Seimiya, H | 1 |
| Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A | 1 |
| Cervantes-Madrid, D; Dueñas-González, A; Romero, Y | 1 |
| Assanhou, AG; Kong, L; Li, W; Mo, R; Sun, H; Xue, L; Zhang, C; Zhang, L | 1 |
| Giallombardo, M; Gil-Bazo, I; Giovannetti, E; Passiglia, F; Peeters, M; Raez, L; Rolfo, C; Ruiz, R; Russo, A | 1 |
| Briley, LP; Carpenter, C; du Bois, A; Fraser, DJ; Graves, AP; Johnson, T; Kaplowitz, N; King, KS; Mitrica, I; Nelson, MR; Pandite, LN; Powles, T; Spraggs, CF; Stinnett, S; Tada, H; Wang, X; Warren, L; Xu, CF; Xue, Z | 1 |
| Chatelut, E; Imbs, DC; Lafont, T; Négrier, S; Paludetto, MN; Powell, H; Thomas, F; White-Koning, M | 1 |
| Arun, Y; Balachandran, C; Emi, N; Mayakrishnan, S; Muralidharan, D; Perumal, PT | 1 |
| Bachelot, T; Campone, M; Chatelut, E; Diéras, V; Imbs, DC; Isambert, N; Jimenez, M; Joly, F; Lafont, T | 1 |
| Kim, KH; Roberts, CW | 1 |
| Ang, JC; Ang, JE; Asad, YJ; Baird, RD; Box, G; de Bono, JS; de Haven Brandon, A; Derynck, M; Eccles, SA; Friedman, L; Henley, AT; Kaye, SB; Pandher, R; Raynaud, FI; Valenti, M; Vanhaesebroeck, B; Workman, P | 1 |
| Garcia, MH; Marques, F; Morais, TS; Tomaz, AI; Valente, A | 1 |
| Mukherji, M; Subhani, S; Vavilala, DT | 1 |
| Babu, E; Bhutia, YD; Ganapathy, V | 1 |
| Albers, T; Booth, L; Dent, P; Lebedyeva, IO; Poklepovic, A; Roberts, JL; Tavallai, M | 1 |
| Blicher, P; Brokstad, KA; Dalhus, B; Gharbi, N; Kalland, KH; Ke, X; Lin, B; Olsen, JR; Qu, Y; Yuan, X; Zhang, W; Øyan, AM | 1 |
| Beijnen, JH; Bins, S; Huitema, AD; Mathijssen, RH; Schellens, JH; Steeghs, N; van Erp, N; Yu, H | 1 |
| Fujiwara, Y; Horiike, A; Inatani, M; Iwasa, S; Kitazono, S; Kondo, S; Nishio, M; Tamura, K; Tanabe, Y; Tanaka, J; Yamamoto, N; Yanagitani, N | 1 |
| Bruce, JY; Carmichael, L; Eickhoff, J; Jeraj, R; Kolesar, J; Liu, G; Perlman, S; Scarpelli, M | 1 |
| Duffaud, F; Gelderblom, H; Grignani, G; Gronchi, A; Guida, M; Jones, RL; Kasper, B; Katz, D; Kollár, A; Litière, S; Marreaud, S; Safwat, A; Sleijfer, S; Stacchiotti, S; Steeghs, N; Touati, N; van der Graaf, WT | 1 |
| Kim, DE; Kim, S; Kwon, TK; Lee, J; Park, JW | 1 |
| Bandara, NA; Bates, CD; Hoylman, EK; Low, PS; Lu, Y | 1 |
| Hu, X; Liu, H; Pan, T; Tan, R; Tan, W; Wang, S; Wang, Y; Yu, H; Zhong, Z | 1 |
| Farago, AF; Holla, VR; Hong, DS; Khotskaya, YB; Meric-Bernstam, F; Mills Shaw, KR | 1 |
| Beijnen, JH; Huitema, ADR; Schellens, JHM; Steeghs, N; Verheijen, RB | 1 |
| Groessl, M; Hartinger, CG; Jarosz, M; Keppler, BK; Polec-Pawlak, K | 1 |
| Choueiri, TK | 1 |
| Boloor, A; Cheung, M; Crosby, RM; Davis-Ward, RG; Epperly, AH; Harris, PA; Hinkle, KW; Hunter, RN; Johnson, JH; Knick, VB; Kumar, R; Laudeman, CP; Luttrell, DK; Mook, RA; Nolte, RT; Rudolph, SK; Stafford, JA; Szewczyk, JR; Truesdale, AT; Veal, JM; Wang, L | 1 |
| Ahmadi, K; Alderton, WK; Alix, S; Baker, SJ; Box, G; Chuckowree, IS; Clarke, PA; Depledge, P; Eccles, SA; Folkes, AJ; Friedman, LS; Hancox, TC; Hayes, A; Kugendradas, A; Lensun, L; Moore, P; Olivero, AG; Pang, J; Patel, S; Pergl-Wilson, GH; Raynaud, FI; Robson, A; Saghir, N; Salphati, L; Shuttleworth, SJ; Sohal, S; Ultsch, MH; Valenti, M; Wallweber, HJ; Wan, NC; Wiesmann, C; Workman, P; Zhyvoloup, A; Zvelebil, MJ | 1 |
| Scheinfeld, NS; Sloan, B | 1 |
| Alex, D; Drescher, A; Grubert, M; Henke, MM; Hilger, RA; Jaehde, U; Richly, H; Scheulen, ME; Thyssen, D | 1 |
| Dittrich, C; Drescher, A; Hartinger, CG; Henke, M; Hilger, RA; Jaehde, U; Keppler, BK; Lentz, F; Lindauer, A; Scheulen, ME | 1 |
| Harada, H; Hiraoka, M; Itasaka, S; Morinibu, A; Shinomiya, K; Xie, X; Zeng, L; Zhu, Y | 1 |
| Albert, DH; Banfor, PN; Cox, BF; Davidsen, SK; Franklin, PH; Fryer, RM; Gintant, GA; Larson, KJ; Noonan, WT; Segreti, JA; Tapang, P; Widomski, DL | 1 |
| Dowlati, A; Gibson, DM; Hodge, JP; Hurwitz, HI; Merkle, EM; Pandite, L; Saini, S; Savage, S; Suttle, AB | 1 |
| Fenton, BM; Paoni, SF | 1 |
| Chen, CS; Goh, BC; Gupta, N; Hartono, S; Humerickhouse, R; Koh, TS; Lee, SC; Lim, R; Lim, SE; McKeegan, E; Ong, AB; Pradhan, R; Soo, R; Steinberg, J; Sukri, N; Thng, CH; Wong, CI; Wong, J; Yong, WP | 1 |
| Altamura, S; Boueres, J; Ferrigno, F; Fonsi, M; Giomini, C; Jones, P; Lamartina, S; Monteagudo, E; Ontoria, JM; Orsale, MV; Palumbi, MC; Pesci, S; Roscilli, G; Rowley, M; Scarpelli, R; Schultz-Fademrecht, C; Toniatti, C | 1 |
| Castaneda, CA; Gomez, HL | 1 |
| Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC | 1 |
| Limvorasak, S; Posadas, EM | 1 |
| Hutson, TE; Sonpavde, G; Sternberg, CN | 1 |
| Koh, MY; Powis, G; Spivak-Kroizman, TR | 1 |
| Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C | 1 |
| Kelly, RJ; Rixe, O | 1 |
| Dan, S; Kong, D; Yamazaki, K; Yamori, T | 1 |
| Clarke, PA; Raynaud, FI; van Montfort, RL; Workman, P | 1 |
| Hashimoto, J; Itoh, K; Minami, H; Mukai, H; Mukohara, T; Nagai, S; Nakajima, H; Umeyama, Y | 1 |
| Silva, Dde O | 1 |
| Choueiri, TK; Schutz, FA; Sternberg, CN | 1 |
| Hamberg, P; Sleijfer, S; Verweij, J | 1 |
| Betof, AS; Dewhirst, MW; Dreher, MR; Hanna, G; Nixon, AB; Spasojevic, I; Tailor, TD; Yarmolenko, PS | 1 |
| Ratain, MJ | 1 |
| Cantley, LC; Myers, AP | 1 |
| Arumugham, T; Dandamudi, UB; Dar, MM; Goh, BC; Hodge, JP; Lager, J; Laubscher, KH; Lewis, LD; Peckham, T; Reddy, NJ; Suttle, AB; Xu, CF; Xu, Y | 1 |
| Goldstein, R; Larkin, J; Pickering, L | 1 |
| Guo, F; Khamly, K; Michael, M; Olszanski, AJ; Pierce, KJ; Vlahovic, G | 1 |
| Arumugham, T; Chiorean, EG; Dar, MM; Forman, K; Gainer, SD; Heath, EI; Hodge, JP; Lager, JJ; LoRusso, P; Malburg, L; Suttle, AB; Sweeney, CJ | 1 |
| Han, DC; Han, YM; Kim, JA; Kwon, BM; Lee, JS; Lee, YJ; Shin, DS; Shin, KD; Yoon, YJ | 1 |
| Arumugham, T; Burris, HA; Dar, MM; Dowlati, A; Fang, L; Gainer, SD; Hodge, JP; Infante, JR; Jones, SF; Lager, JJ; Nishioka, J; Suttle, AB; Tan, AR | 1 |
| Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
| Chayahara, N; Fujiwara, Y; Kiyota, N; Minami, H; Mukohara, T; Suzuki, A; Umeyama, Y | 1 |
| Bair, AH; Cohen, EE; Fruehauf, JP; Kim, S; Letrent, KJ; Olszanski, AJ; Ricart, AD; Rini, BI; Rixe, O; Rosbrook, B; Schiller, JH; Tarazi, JC | 1 |
| Chen, JK; Chung, TH; Huang, DM; Yen-Ping Kuo, M | 1 |
| Czyz, M; Duechler, M; Wilczynski, J | 1 |
| Bergamo, A; Sava, G | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
| Adams, L; Ball, H; Forman, K; Gainer, S; Heath, EI; LoRusso, P; Malburg, L; Suttle, AB | 1 |
| Bloem, L; Chen, D; Chen, Z; Henry, JR; Huss, K; Li, HY; Li, WY; McCann, DJ; Peng, SB; Zhai, Y; Zhao, G; Zia-Ebrahimi, M | 1 |
| Alarcon, SV; Brega, N; Crandon, S; Figg, WD; Giaccone, G; Gutierrez, M; Houk, BE; Jain, L; Kelly, RJ; Kim, YS; Kummar, S; Mannargudi, B; Rajan, A; Shnaidman, M; Trepel, JB; Zein, WM | 1 |
| Amiji, M; Duan, Z; Milane, L | 1 |
| Berndt, A; Burke, JE; Vadas, O; Williams, RL; Zhang, X | 1 |
| Goozner, M | 1 |
| Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA | 1 |
| Ansell, PJ; Asahina, H; Carlson, DM; Chiu, YL; Coates, A; Goto, Y; Li, X; McKee, MD; McKeegan, EM; Nokihara, H; Pradhan, R; Seki, Y; Shibata, T; Tamura, T; Tamura, Y; Tanioka, M; Yamada, Y; Yamamoto, N | 1 |
| Döme, B; Török, S | 1 |
| André, S; Bleich, D; Gabius, HJ; Huet, G; Kaltner, H; Kopitz, J; Ledeen, RW; Wu, G | 1 |
| Chen, SP; Chen, XG; Cheng, C; Fu, LW; Liang, YJ; Liu, Z; Mi, YJ; To, KK; Wang, F; Wu, XP | 1 |
| Arena, S; Bardelli, A; Belvin, M; Eastham-Anderson, J; Edgar, KA; Francis, R; Friedman, LS; Goodall, JE; Griffin, S; Grimshaw, KM; Guan, J; Haverty, PM; Hoeflich, KP; Torrance, C; Torres, AC; Wallin, JJ; Zhou, W | 1 |
| Benes, C; Carlson, C; Eck, M; Gray, N; Liu, Q; Ni, J; Riddle, S; Roberts, T; Vogel, K; Von, T; Xie, S; Zhao, J | 1 |
| Ball, HA; Burris, HA; Dar, MM; Dowlati, A; Gainer, SD; Infante, JR; Jones, SF; Levinson, KT; Lindquist, D; Moss, RA; Spigel, DR; Suttle, AB; Tan, AR | 1 |
| Arion, VB; Berger, W; Büchel, GE; Heffeter, P; Hejl, M; Jakupec, MA; Keppler, BK; Stepanenko, IN | 1 |
| Carmichael, C; Josephson, DY; Lau, C; Pal, SK | 1 |
| Cleary, J; Howard, SA; Jagannathan, JP; Krajewski, KM; O'Regan, K; Ramaiya, N; Thornton, E | 1 |
| Bing, N; de Souza, PL; Goodman, VL; King, KS; McCann, LA; Mooser, VE; Pandite, LN; Spraggs, CF; Xu, CF; Xue, Z | 1 |
| Arriola, E; Cohen, RB; De Castro Carpeño, J; Herbst, RS; Kim, S; Kozloff, MF; Krzakowski, M; Martin, LP; Olszanski, AJ; Rado, TA; Rosbrook, B; Samuel, TA; Tarazi, J; Tortorici, M | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Alessi, DR; Najafov, A; Shpiro, N | 1 |
| Arumugham, T; de Jonge, MJ; Hamberg, P; Hodge, J; Hurwitz, HI; Pandite, LN; Savage, S; Suttle, AB; Verweij, J | 1 |
| Ball, HA; Botbyl, J; Gibson, DM; Jeffels, M; Madi, A; Nokay, B; Plummer, R; Richly, H; Rubin, S; Scheulen, ME; Weller, S | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Adjei, AA; Allen, R; Bendell, JC; Burris, HA; Dy, GK; Huff, A; Infante, JR; Ma, WW; Novello, S; Ottesen, LH; Suttle, AB; Wang, Q; Xu, CF | 1 |
| Manley, E; Waxman, DJ | 1 |
| Ball, HA; Dar, MM; Heath, EI; Infante, J; Kasubhai, S; Kleha, JF; Lewis, LD; LoRusso, P; Luu, T; Ma, B; Stephenson, J; Suttle, AB; Tan, AR | 1 |
| Arumugham, T; de Souza, P; Suttle, AB | 1 |
| Donehower, RC; Pili, R | 1 |
| Cho, YS; Chun, YS; Kim, J; Kim, MS; Lee, JC; Park, JW; Yeo, EJ | 1 |
| Chun, YS; Park, JW; Yeo, EJ | 2 |
| Clottes, E | 1 |
| Chang, JH; Chang, YL; Cheng, FC; Guh, JH; Kuo, SC; Lee, FY; Pan, SL; Peng, CY; Teng, CM; Wang, SW | 1 |
| Bouska, JJ; de Jong, R; Giranda, VL; Gramling-Evans, EE; Guan, R; Han, EK; Johnson, EF; Klinghofer, V; Leverson, JD; Li, Q; Li, T; Liu, X; Luo, Y; Mamo, M; McGonigal, TP; Mika, AK; Mitten, MJ; Nguyen, PT; Oleksijew, A; Oltersdorf, T; Powlas, JA; Rosenberg, SH; Shi, Y; Shoemaker, AR; Smith, RA; Stoll, VS; Thomas, SA; Woods, KW; Zinker, BA | 1 |
| Collins, JM | 1 |
| Freddo, JL; Herbst, RS; Kies, MS; Liu, G; Park, JW; Pithavala, YK; Reich, SD; Rugo, HS; Steinfeldt, HM; Wilding, G | 1 |
| Garber, K | 1 |
| Anderson, MG; Fesik, SW; Giranda, VL; Leverson, JD; Li, Q; Luo, Y; Morgan-Lappe, S; Schurdak, ME; Woods, KW | 1 |
| Groessl, M; Hann, S; Hartinger, CG; Keppler, BK; Koellensperger, G; Rudnev, AV; Stingeder, G; Sulyok, M; Timerbaev, AR | 1 |
| Kim, TY; Ko, JH; Park, RE; Ryu, CK; Ryu, JS; Song, EH; Yeon, SW; You, HJ | 1 |
| Brooks, P; Davis, R; Freimark, B; Hu-Lowe, DD; Inai, T; Mancuso, MR; McDonald, DM; Nakahara, T; Norberg, SM; O'Brien, S; Sennino, B; Shalinsky, DR; Yao, VJ | 1 |
| Hutson, TE; Sonpavde, G | 1 |
| Kibble, A | 1 |
| Kibble, A; Shumoogam, J; Walker, K | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Ma, J; Waxman, DJ | 1 |
| Bombieri, G; Cascioferro, S; Daidone, G; Di Cristina, A; Gallo, G; Grimaudo, S; Maggio, B; Meneghetti, F; Pipitone, RM; Plescia, S; Raffa, D; Raimondi, MV; Schillaci, D; Tolomeo, M | 1 |
| Battelli, T; D'Atri, S; De Martino, C; Floridi, A; Gallo, M; Malorni, W; Marcante, ML; Nista, A; Paggi, MG | 1 |
| Band, PR; Besner, JG; Catanese, B; De Sanctis, AJ; Deschamps, M; Leclaire, R | 1 |
| Band, PR; Besner, JG; De Sanctis, A; Deschamps, M; Gervais, P; Leclaire, R | 2 |
| Currie, VE; Farag, FM; Kim, JH; Kinahan, JE; O'Hehir, MA; Young, CW | 1 |
| Evans, WK; Mullis, B; Shepherd, FA | 1 |
| Barduagni, A; Barduagni, M; Ciottoli, GB; Delle Chiaie, S; Di Lauro, L; Gallo Curcio, C; Nardi, M; Tonachella, R | 1 |
| Battelli, T; Bellocci, M; Cavaliere, R; De Martino, C; Di Filippo, F; Gallo Curcio, C; Giustini, L; Manocchi, D; Mattioli, R; Rinaldi, M | 1 |
| Teicher, BA | 1 |
| Chen, LK; Hall, ES; Hall, IH; Wong, OT | 1 |
| Chevallier, B | 2 |
| Furue, H; Niitani, H; Ogawa, N; Ohta, K; Suminaga, M; Taguchi, T | 1 |
| Dees, EC; Donehower, RC; Grochow, LB; Grove, WR; Rummel, S; Whitfield, LR | 1 |
| Anderson, PM; Arndt, CA; Krailo, MD; Liu-Mares, W; Reaman, GH | 1 |
| Artico, M; Gatto, MT; Saso, L; Tita, B | 1 |
| Bremer, K; Uhlenbusch, R | 1 |
| Frei, E; Teicher, BA | 1 |
| Goa, KL; Plosker, GL | 1 |
| Arancia, G; Donelli, G | 1 |
| Danjoux, CE; DeSanctis, AJ; Feeley, MM; Fisher, B; Maroun, J; Martin, L; Raaphorst, GP | 1 |
| Soukop, M | 1 |
| Caubel, M; Cupissol, DR; Serrou, B | 1 |
| Weinerman, B | 1 |
| Falkson, G; van Zyl, AJ | 1 |
| Alfieri, AA; He, SQ; Kim, JH; Kim, SH; Young, CW | 1 |
| Hugander, A; Lagoni, RK; Longo, WL; Neville, AJ; Riggs, C; Robins, HI; Schmitt, CL | 1 |
| Caputo, A; Fanciulli, M; Floridi, A; Paggi, MG; Perrotti, N; Silvestrini, B; Zeuli, M | 1 |
76 review(s) available for indazoles and Benign Neoplasms
| Article | Year |
|---|---|
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.
Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase Inhibitor Proteins; Humans; Neoplasms | 2015 |
Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.
Topics: Benzamides; Gene Fusion; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy.
Topics: Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinolines; Sulfonamides; Tyrosine | 2022 |
Recent Development of Heterocyclic Compounds with Indazole Moiety as Potential Antiparasitic Agents.
Topics: Antiparasitic Agents; Heterocyclic Compounds; Humans; Indazoles; Neoplasms; Structure-Activity Relationship | 2022 |
TRK inhibitors in TRK fusion-positive cancers.
Topics: Animals; Antineoplastic Agents; Benzamides; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Indazoles; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2019 |
How I treat
Topics: Benzamides; Biomarkers, Tumor; Gene Fusion; Genetic Testing; Humans; Indazoles; Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptors, Nerve Growth Factor; Time Factors; Treatment Outcome | 2019 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
Topics: Animals; Benzamides; Drug Design; Drug Development; Humans; Indazoles; Membrane Glycoproteins; Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services.
Topics: Adult; Benzamides; Delivery of Health Care; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2020 |
The Anticancer Activity of Indazole Compounds: A Mini Review.
Topics: Antineoplastic Agents; Humans; Indazoles; Neoplasms; Structure-Activity Relationship | 2021 |
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
Topics: Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA | 2021 |
Evolving role of entrectinib in treatment of
Topics: Animals; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Disease Models, Animal; Drug Approval; Drug Evaluation, Preclinical; Humans; Indazoles; Membrane Glycoproteins; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC | 2021 |
Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Azepines; Benzamides; Drug Approval; Drug Resistance; Drug Screening Assays, Antitumor; Flavones; Gene Expression Regulation; Humans; Indazoles; Neoplasms; Organophosphates; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2021 |
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
Topics: Adverse Drug Reaction Reporting Systems; Humans; Incidence; Indazoles; Neoplasms; Phthalazines; Piperazines; Piperidines; Pneumonia; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Time Factors | 2021 |
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
Topics: Humans; Indazoles; Indoles; Neoplasms; Network Meta-Analysis; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
PharmGKB summary: pazopanib pathway, pharmacokinetics.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gene Regulatory Networks; Humans; Indazoles; Neoplasms; Pharmacogenomic Variants; Pyrimidines; Sulfonamides; Treatment Outcome | 2017 |
Fatigue associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis.
Topics: Anilides; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Neoplasms; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Neoplasms; Neovascularization, Pathologic; Pyrimidines; Sulfonamides | 2017 |
The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
Topics: Animals; Antineoplastic Agents; Cell Death; Coordination Complexes; Dimethyl Sulfoxide; Drug Discovery; History, 20th Century; History, 21st Century; Humans; Indazoles; Models, Molecular; Molecular Structure; Neoplasms; Organometallic Compounds; Protein Binding; Ruthenium Compounds; Structure-Activity Relationship; Tissue Distribution | 2018 |
Drug review: Pazopanib.
Topics: Animals; Clinical Trials as Topic; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides | 2018 |
Indazole Derivatives: Promising Anti-tumor Agents.
Topics: Animals; Antineoplastic Agents; Aurora Kinases; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Drug Design; Fusion Proteins, bcr-abl; Humans; Hypoxia-Inducible Factor 1; Indazoles; Indoleamine-Pyrrole 2,3,-Dioxygenase; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Receptors, Fibroblast Growth Factor; Structure-Activity Relationship | 2018 |
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
Topics: Angiogenesis Inhibitors; Humans; Indazoles; Liver; Neoplasms; Pyrimidines; Retrospective Studies; Risk Factors; Sulfonamides | 2013 |
Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Axitinib; Clinical Trials as Topic; Humans; Hypertension; Imidazoles; Incidence; Indazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Risk | 2013 |
Clinical pharmacology of axitinib.
Topics: Axitinib; Drug Interactions; Humans; Imidazoles; Indazoles; Intestinal Absorption; Neoplasms; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor | 2013 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Cardiovascular Diseases; Humans; Imidazoles; Incidence; Indazoles; Indoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk; Sunitinib | 2014 |
Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Axitinib; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Models, Biological; Neoplasms; Nonlinear Dynamics; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sex Factors; Tissue Distribution; Young Adult | 2014 |
Axitinib plasma pharmacokinetics and ethnic differences.
Topics: Area Under Curve; Asian People; Axitinib; China; Clinical Trials as Topic; Disease-Free Survival; Half-Life; Humans; Imidazoles; Indazoles; Japan; Metabolic Clearance Rate; Neoplasms; Protein Kinase Inhibitors; Vascular Endothelial Growth Factors; White People | 2015 |
Drug discovery using spirooxindole cores: Success and Challenges [corrected].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Drug Discovery; Humans; Indazoles; Indoles; Neoplasms; Protein Serine-Threonine Kinases; Structure-Activity Relationship | 2015 |
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Indazoles; Liver; Male; Middle Aged; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides; Young Adult | 2015 |
Linifanib: current status and future potential in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indazoles; Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Protein Kinase Inhibitors | 2015 |
[Cancer therapy by PARP inhibitors].
Topics: Antineoplastic Agents; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; DNA Breaks, Double-Stranded; DNA Replication; DNA, Single-Stranded; Enzyme Inhibitors; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Mutation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair | 2015 |
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Diazooxonorleucine; Humans; Indazoles; Neoplasms | 2015 |
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor, trkA; Receptor, trkB; Receptor, trkC | 2015 |
Targeting EZH2 in cancer.
Topics: Benzamides; Biphenyl Compounds; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Morpholines; Mutation; Neoplasms; Polycomb Repressive Complex 2; Polycomb-Group Proteins; Pyridones | 2016 |
Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds.
Topics: Antineoplastic Agents; Cell Line, Tumor; Coordination Complexes; Cyclopentanes; Dimethyl Sulfoxide; Drug Discovery; Ferrous Compounds; Humans; Indazoles; Molecular Targeted Therapy; Neoplasms; Organometallic Compounds; Protein Binding; Ruthenium; Ruthenium Compounds | 2016 |
HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Anthracyclines; Biphenyl Compounds; Cardiac Glycosides; Humans; Hypoxia-Inducible Factor 1; Indazoles; Lignans; Models, Biological; Neoplasms; Neovascularization, Pathologic; Retinal Neovascularization; Vascular Endothelial Growth Factors | 2016 |
Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine.
Topics: Antineoplastic Agents; Glycolysis; Humans; Indazoles; Neoplasms; Signal Transduction | 2016 |
The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance.
Topics: Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; Fatty Acids; Humans; Indazoles; Metabolic Engineering; Neoplasms; Oxidative Phosphorylation; Pyruvates | 2017 |
Targeting TRK family proteins in cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Humans; Indazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC | 2017 |
Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
Topics: Angiogenesis Inhibitors; Animals; Dose-Response Relationship, Drug; Humans; Indazoles; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2017 |
Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Contraindications; Humans; Imidazoles; Indazoles; Neoplasms; Patents as Topic; Randomized Controlled Trials as Topic; Structure-Activity Relationship | 2008 |
Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
Topics: Animals; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Drugs, Investigational; Humans; Indazoles; Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2008 |
Pazopanib: an antiangiogenic drug in perspective.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides | 2009 |
Pazopanib: therapeutic developments.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indazoles; Kidney Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vascular Endothelial Growth Factors | 2009 |
Pazopanib for the treatment of renal cell carcinoma and other malignancies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Humans; Indazoles; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2009 |
HIF-1alpha and cancer therapy.
Topics: Animals; Cell Hypoxia; Histone Deacetylase Inhibitors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mustard Compounds; Neoplasms; Phenylpropionates; Proto-Oncogene Proteins c-myc; Tumor Suppressor Protein p53 | 2010 |
Compounds in clinical Phase III and beyond.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2010 |
Axitinib (AG-013736).
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Biological Availability; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Imidazoles; Indazoles; Neoplasms; Pancreatic Neoplasms; Thyroid Neoplasms | 2010 |
Drugging the PI3 kinome: from chemical tools to drugs in the clinic.
Topics: Animals; Drug Delivery Systems; Furans; Humans; Indazoles; Models, Molecular; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sulfonamides | 2010 |
Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Dimethyl Sulfoxide; Glioblastoma; Humans; Indazoles; Ligands; Neoplasms; Organometallic Compounds; Organoplatinum Compounds; Rats; Ruthenium; Ruthenium Compounds; Solubility | 2010 |
Pazopanib: Clinical development of a potent anti-angiogenic drug.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides | 2011 |
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Disease-Free Survival; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Linifanib.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor | 2010 |
Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors | 2010 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Clinical Trials as Topic; Estradiol; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mice; Neoplasms; NF-kappa B; Topotecan; Transcription Factors; Tumor Cells, Cultured | 2011 |
Structural basis for activation and inhibition of class I phosphoinositide 3-kinases.
Topics: Enzyme Activation; Humans; Indazoles; Models, Molecular; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Protein Subunits; Signal Transduction; Sulfonamides | 2011 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Beyond glycoproteins as galectin counterreceptors: tumor-effector T cell growth control via ganglioside GM1 [corrected].
Topics: Animals; Anoikis; Cell Communication; G(M1) Ganglioside; Galectins; Glycoproteins; Humans; Indazoles; Mice; Models, Immunological; Morpholines; Neoplasms; Propionates; Signal Transduction; T-Lymphocytes | 2012 |
Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors | 2012 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Hypertension; Incidence; Indazoles; Neoplasms; Prospective Studies; Publication Bias; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Risk; Sulfonamides | 2013 |
Versatile pharmacological actions of YC-1: anti-platelet to anticancer.
Topics: Animals; Antineoplastic Agents; Cyclic GMP; Guanylate Cyclase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Neoplasms; Platelet Aggregation Inhibitors; Transcription Factors | 2004 |
New anticancer strategies targeting HIF-1.
Topics: Adaptation, Physiological; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA-Binding Proteins; Gene Targeting; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Neoplasms; Nuclear Proteins; Transcription Factors | 2004 |
[Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy].
Topics: Animals; Cell Hypoxia; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Isoquinolines; Mice; Neoplasm Proteins; Neoplasms; Nuclear Proteins; RNA, Messenger; Transcription Factors; Transcriptional Activation; Transplantation, Heterologous | 2005 |
Pazopanib: a novel multitargeted tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Lonidamine: in vitro/in vivo correlations.
Topics: Antineoplastic Agents; Drug Administration Schedule; Humans; Indazoles; Neoplasms; Tumor Cells, Cultured | 1994 |
Recent studies on lonidamine, the lead compound of the antispermatogenic indazol-carboxylic acids.
Topics: alpha-Macroglobulins; Animals; Antineoplastic Agents; Antispermatogenic Agents; Humans; Indazoles; Male; Neoplasms; Proteins; Rats; Testis | 2002 |
Modulation of antitumor alkylating agents (AA).
Topics: Alkylating Agents; Antineoplastic Agents; Cell Hypoxia; Cisplatin; DNA Damage; DNA Repair; Drug Combinations; Drug Interactions; Drug Resistance; Fluorocarbons; Glutathione; Glutathione Transferase; Humans; Hydroxyethyl Starch Derivatives; Indazoles; Metallothionein; Neoplasm Proteins; Neoplasms; Nitroimidazoles; Oxygen; Radiation-Sensitizing Agents; Topoisomerase II Inhibitors; Xanthines | 1991 |
Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
Topics: Animals; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Indazoles; Male; Nausea; Neoplasms; Serotonin Antagonists; Vomiting | 1991 |
Cell membranes as target for anticancer agents.
Topics: Antineoplastic Agents; Cell Division; Cell Membrane; Doxorubicin; Erythrocyte Membrane; Humans; Indazoles; Lymphocytes; Microscopy, Electron; Neoplasms | 1991 |
74 trial(s) available for indazoles and Benign Neoplasms
| Article | Year |
|---|---|
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Follow-Up Studies; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Protein Kinase Inhibitors; Tissue Distribution; Young Adult | 2021 |
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Humans; Indazoles; Neoplasms; Paclitaxel; Piperidines; Vascular Endothelial Growth Factor A | 2022 |
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasms; Progression-Free Survival; Pyrimidines; Sulfonamides; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Benzimidazoles; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Prognosis; Ramucirumab | 2021 |
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Capsules; Cross-Over Studies; Fasting; Feces; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Indazoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Therapeutic Equivalency; Young Adult | 2021 |
The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study.
Topics: Adult; Aged; Cohort Studies; Female; Humans; Indazoles; Japan; Male; Middle Aged; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2021 |
VOTRAGE study: Phase I dose-escalation study of pazopanib in unfit older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Indazoles; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome | 2021 |
Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cardiac Output; Endothelium, Vascular; Female; Hemodynamics; Humans; Hypertension; Indazoles; Male; Middle Aged; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vascular Resistance; Vascular Stiffness | 2021 |
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatocyte Growth Factor; Humans; Indazoles; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Pyrrolidinones; Quinolines; Sulfonamides; Vascular Endothelial Growth Factor A | 2021 |
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides | 2017 |
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Animals; Biological Availability; Cell Line, Tumor; Diarrhea; Dogs; Dose-Response Relationship, Drug; Drug Eruptions; Drug Evaluation, Preclinical; Fatigue; Female; Humans; Indazoles; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nausea; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Rats; Triazoles; Xenograft Model Antitumor Assays; Young Adult | 2018 |
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients.
Topics: Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Female; Heterozygote; Humans; Indazoles; Male; Middle Aged; Models, Biological; Neoplasms; Polymorphism, Single Nucleotide; Pyrimidines; Sulfonamides | 2019 |
Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.
Topics: Adult; Age Factors; Aged; Azepines; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Patient Safety; Pyrimidines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Risk Assessment; Sex Factors; Sulfonamides; Survival Analysis; Treatment Outcome | 2019 |
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Class I Phosphatidylinositol 3-Kinases; Female; GTP Phosphohydrolases; Humans; Indazoles; Male; Membrane Proteins; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sulfonamides; Treatment Outcome; Young Adult | 2020 |
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Neutropenia; Protein Serine-Threonine Kinases | 2019 |
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Esomeprazole; Female; Humans; Indazoles; Ketoconazole; Male; Middle Aged; Neoplasms; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2013 |
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Female; Humans; Indazoles; Liver Diseases; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases | 2013 |
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Cohort Studies; Female; Follow-Up Studies; Heterozygote; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Prostatic Neoplasms; Tissue Distribution | 2013 |
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Indazoles; Male; Neoplasms; Pyrimidines; Sarcoma; Sulfonamides; Young Adult | 2013 |
Exposure-response (safety) analysis to identify linifanib dose for a Phase III study in patients with hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Pharmaceutical Solutions; Phenylurea Compounds; Tablets; Young Adult | 2013 |
Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors.
Topics: Cross-Over Studies; Electrocardiography; Humans; Indazoles; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2014 |
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Endothelial Cells; Female; Humans; Ifosfamide; Indazoles; Male; Middle Aged; Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Pyrimidines; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2014 |
Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Lapatinib; Male; Middle Aged; Neoplasms; Pyrimidines; Quinazolines; Sulfonamides | 2014 |
Phase I Study of Pazopanib and Ixabepilone in Patients With Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytokines; Disease-Free Survival; E-Selectin; Epothilones; Fatigue; Female; Humans; Indazoles; Male; Middle Aged; Neoplasms; Neutropenia; Pyrimidines; Retreatment; Sulfonamides; Survival Rate; Thrombocytopenia | 2016 |
Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Circadian Rhythm; Cross-Over Studies; Drug Administration Schedule; Fatigue; Female; Food-Drug Interactions; Half-Life; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Male; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index | 2014 |
An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Carbazoles; Cell Line; Endothelial Cells; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Swine; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Benzamides; Biological Availability; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Glycine; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Vision Disorders | 2014 |
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides | 2015 |
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2015 |
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Taxoids | 2015 |
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasms; Neovascularization, Pathologic; Proportional Hazards Models; Protein Stability; Proteolysis; Pyrimidines; Sulfonamides; Texas; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53; Vorinostat; Young Adult | 2015 |
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indazoles; Male; Middle Aged; Mutation; Neoplasm Staging; Neoplasms; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomography.
Topics: Adult; Aged; Axitinib; Dideoxynucleosides; Disease Progression; Female; Fluorine Radioisotopes; Humans; Imidazoles; Indazoles; Male; Middle Aged; Multimodal Imaging; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Substance Withdrawal Syndrome; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2015 |
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gene Amplification; Humans; Indazoles; Lapatinib; Male; Middle Aged; Mutation; Neoplasms; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides | 2015 |
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.
Topics: Antineoplastic Agents; Binding Sites; Blood Proteins; Case-Control Studies; Chromatography, High Pressure Liquid; Humans; In Vitro Techniques; Indazoles; Neoplasms; Protein Binding; Pyrimidines; Serum Albumin; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Pharmacokinetic interaction between pazopanib and cisplatin regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome | 2016 |
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Indazoles; Mass Spectrometry; Metabolome; Metabolomics; Mice; Neoplasm Transplantation; Neoplasms; PTEN Phosphohydrolase; Sulfonamides; Time Factors | 2016 |
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carboplatin; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Sulfonamides; Treatment Outcome | 2017 |
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Female; Follow-Up Studies; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Indazoles; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sulfonamides; Survival Rate; Tunica Intima | 2017 |
Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
Topics: Antineoplastic Agents; Blood Chemical Analysis; Blood Proteins; Electrophoresis, Capillary; Humans; In Vitro Techniques; Indazoles; Mass Spectrometry; Neoplasms; Organometallic Compounds; Protein Binding; Ruthenium Compounds; Serum Albumin; Transferrin | 2008 |
Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents; Area Under Curve; Female; Humans; Indazoles; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Organometallic Compounds; Ruthenium Compounds | 2009 |
Phase I trial of pazopanib in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Anorexia; Cohort Studies; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrimidines; Sulfonamides; Vomiting | 2009 |
Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hypertension; Indazoles; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Treatment Outcome | 2010 |
Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Axitinib; Biomarkers; Fatigue; Female; Humans; Hypertension; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Thyrotropin; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Genotype; Humans; Indazoles; Isoenzymes; Male; Middle Aged; Molecular Probes; Neoplasms; New Hampshire; Phenotype; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Singapore; Substrate Specificity; Sulfonamides; Treatment Outcome | 2010 |
Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bilirubin; Creatinine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Patient Selection; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2010 |
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Cohort Studies; Cross-Over Studies; Dietary Fats; Fatigue; Female; Food-Drug Interactions; Humans; Hypertension; Indazoles; Male; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides | 2010 |
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Asian People; Axitinib; Biomarkers; Fatigue; Female; Humans; Hyperthyroidism; Hypothyroidism; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-kit; Thyroglobulin; Thyrotropin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Demography; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Pyrimidines; Sulfonamides; Suspensions; Tablets; Time Factors; Treatment Outcome | 2012 |
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Topics: Adult; Aged; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glycine; HSP90 Heat-Shock Proteins; Humans; Indazoles; Lymphoma; Male; Middle Aged; Neoplasms | 2011 |
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Tolerance; Female; Humans; Indazoles; Male; Membrane Proteins; Middle Aged; Neoplasms; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases | 2012 |
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides; Treatment Outcome | 2012 |
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides; Young Adult | 2013 |
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Indazoles; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Demography; Dose-Response Relationship, Drug; Female; Glutamates; Guanine; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pemetrexed; Pyrimidines; Sulfonamides | 2013 |
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Anti-Bacterial Agents; Aza Compounds; Blood Pressure; Confidence Intervals; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Heart Rate; Humans; Indazoles; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Neoplasms; Pyrimidines; Quinolines; Sulfonamides; Young Adult | 2013 |
Bayesian methods for pharmacokinetic/pharmacodynamic modeling of pazopanib-induced increases in blood pressure and transaminases.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Angiogenesis Inhibitors; Aspartate Aminotransferases; Bayes Theorem; Blood Pressure; Humans; Indazoles; Logistic Models; Middle Aged; Models, Biological; Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Young Adult | 2013 |
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Axitinib; Drug Administration Schedule; Drug Interactions; Female; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Treatment Outcome | 2005 |
The control of acute cisplatin-induced emesis--a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Granisetron Study Group.
Topics: Blood Pressure; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Indazoles; Male; Metoclopramide; Middle Aged; Nausea; Neoplasms; Pulse | 1993 |
[Clinical evaluation of granisetron for nausea and vomiting induced by anticancer drugs--optimal dose-finding study].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Cisplatin; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Vomiting | 1993 |
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; DNA; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Intercalating Agents; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Time Factors | 2000 |
Phase I study of CI-958 in children and adolescents with recurrent solid tumors.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Hypotension; Indazoles; Infusions, Intravenous; Male; Neoplasms; Neutropenia | 2001 |
[Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Granisetron; Humans; Ifosfamide; Indazoles; Male; Middle Aged; Neoplasms; Pyrrolidines; Serotonin Antagonists; Single-Blind Method | 1991 |
Granisetron. A review of its pharmacological properties and therapeutic use as an antiemetic.
Topics: Animals; Antiemetics; Antineoplastic Agents; Female; Granisetron; Humans; Indazoles; Male; Nausea; Neoplasms; Serotonin Antagonists; Vomiting | 1991 |
A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. The Granisetron Study Group.
Topics: Cisplatin; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Serotonin Antagonists; Time Factors; Vomiting | 1990 |
The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis.
Topics: Adult; Aged; Cisplatin; Double-Blind Method; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Serotonin Antagonists; Sex Factors; Time Factors; Vomiting | 1990 |
Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.
Topics: Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Headache; Humans; Indazoles; Male; Metoclopramide; Middle Aged; Neoplasms; Serotonin Antagonists; Single-Blind Method; Vomiting | 1990 |
Lonidamine and human lymphoblastoid alpha interferon in metastatic cancer: a phase I study.
Topics: Activities of Daily Living; Adult; Aged; Drug Administration Schedule; Drug Synergism; Female; Humans; Indazoles; Interferon Type I; Male; Middle Aged; Neoplasms | 1990 |
126 other study(ies) available for indazoles and Benign Neoplasms
| Article | Year |
|---|---|
Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Escherichia coli; HSP90 Heat-Shock Proteins; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Neoplasms; Reproducibility of Results; Structure-Activity Relationship; Surface Plasmon Resonance; Triazines; Xenograft Model Antitumor Assays | 2011 |
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Topics: Benzamides; Biomarkers, Tumor; Circulating Tumor DNA; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Neoplasm Staging; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA | 2022 |
Response to comment on "Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications".
Topics: Benzamides; Humans; Indazoles; Neoplasms | 2021 |
Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'.
Topics: Benzamides; Humans; Indazoles; Neoplasms | 2021 |
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Topics: Enzyme Inhibitors; Humans; Indazoles; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455.
Topics: Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Radiation-Sensitizing Agents | 2022 |
A water-dependent reversible photoacidity strategy for cancer treatment.
Topics: Indazoles; Neoplasms; Oxygen; Phototherapy; Protons; Water | 2022 |
Lonidamine and domperidone inhibit expansion of transformed cell areas by modulating motility of surrounding nontransformed cells.
Topics: Animals; Antineoplastic Agents; Domperidone; Drug Screening Assays, Antitumor; Epithelial Cells; Indazoles; Mammary Glands, Animal; Mice; Neoplasms | 2022 |
1H-Indazoles derivatives targeting PI3K/AKT/mTOR pathway: Synthesis, anti-tumor effect and molecular mechanism.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Indazoles; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2023 |
Cost-effectiveness of alternative
Topics: Adult; Benzamides; Cost-Benefit Analysis; Europe; Humans; Indazoles; Neoplasms | 2023 |
Promoting antitumor efficacy by suppressing hypoxia via nano self-assembly of two irinotecan-based dual drug conjugates having a HIF-1α inhibitor.
Topics: A549 Cells; Animals; Antineoplastic Agents; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Receptors, Vascular Endothelial Growth Factor; Tumor Hypoxia | 2019 |
Resistance to TRK inhibition mediated by convergent MAPK pathway activation.
Topics: Adolescent; Adult; Animals; Benzamides; Cell Proliferation; Cell-Free Nucleic Acids; Child; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Imidazoles; Indazoles; Male; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Oximes; Protein Kinase Inhibitors; Pyrazoles; Pyridones; Pyrimidines; Pyrimidinones; Receptor, trkA; Young Adult | 2019 |
FDA notches up third tissue-agnostic cancer approval.
Topics: Benzamides; Drug Approval; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; United States; United States Food and Drug Administration | 2019 |
New Drug Targets Key Genetic Driver of Cancer.
Topics: Benzamides; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2019 |
An enzyme-assisted self-delivery system of lonidamine-peptide conjugates for selectively killing cancer cells.
Topics: Alkaline Phosphatase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Humans; Hydrogels; Indazoles; Mice; Neoplasms; Peptides; Transplantation, Heterologous | 2019 |
Site-agnostic biomarker-guided oncology drug development.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Clinical Decision-Making; Clinical Trials as Topic; Drug Approval; Drug Development; Humans; Indazoles; Molecular Targeted Therapy; Neoplasms; Organ Specificity; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic | 2020 |
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Gene Fusion; Humans; Indazoles; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Metastasis; Neoplasms; Protein Kinase Inhibitors; Receptor, trkA; Receptor, trkB; Receptor, trkC; Receptors, Nerve Growth Factor; Time Factors; Treatment Outcome | 2020 |
The kinase polypharmacology landscape of clinical PARP inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Dyrk Kinases; HEK293 Cells; Humans; Indazoles; Indoles; Isoenzymes; Molecular Docking Simulation; Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polypharmacology; Protein Binding; Protein Interaction Domains and Motifs; Protein Serine-Threonine Kinases; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Substrate Specificity | 2020 |
On the right TRK: from oncogene discovery to cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Mice; Neoplasms; Oncogene Proteins, Fusion; Oncogenes; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA | 2019 |
YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deferoxamine; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Large Neutral Amino Acid-Transporter 1; MCF-7 Cells; Neoplasms; Neutrons; Oxygen; Phenylalanine; Radiation-Sensitizing Agents; RNA, Small Interfering | 2020 |
Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; HEK293 Cells; Humans; Indazoles; Lung Neoplasms; Male; Mice, Inbred NOD; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptor, trkA | 2020 |
Antiproliferative and apoptotic activity of new indazole derivatives as potential anticancer agents.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; G2 Phase Cell Cycle Checkpoints; Humans; Indazoles; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Structure-Activity Relationship | 2020 |
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic
Topics: Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins | 2020 |
FDA Approval Summary: Entrectinib for the Treatment of
Topics: Benzamides; Drug Approval; Humans; Indazoles; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, trkA; Receptor, trkB; Receptor, trkC; United States; United States Food and Drug Administration | 2021 |
[Drug approval : entrectinib and larotrectinib - cancers with NTRK fusion].
Topics: Adult; Benzamides; Child; Drug Approval; France; Humans; Indazoles; Membrane Glycoproteins; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC | 2020 |
Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
Topics: Adult; Age Factors; Benzamides; Child; Consensus; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Membrane Glycoproteins; Molecular Targeted Therapy; Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC; Reverse Transcriptase Polymerase Chain Reaction; Societies, Medical; Spain | 2021 |
Switching on prodrugs using radiotherapy.
Topics: Animals; Antineoplastic Agents; Azides; Doxorubicin; Female; Fluorescent Dyes; Gamma Rays; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxidation-Reduction; Prodrugs; Proof of Concept Study; Pyrimidines; Sulfonamides; X-Rays; Xenograft Model Antitumor Assays | 2021 |
Cancer Cytomembrane-Cloaked Prussian Blue Nanoparticles Enhance the Efficacy of Mild-Temperature Photothermal Therapy by Disrupting Mitochondrial Functions of Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Membrane; Cell Proliferation; Drug Carriers; Drug Liberation; Female; Ferrocyanides; Hep G2 Cells; Humans; Indazoles; Infrared Rays; Mice, Nude; Mitochondria; Nanocomposites; Nanoparticles; Neoplasms; Photothermal Therapy | 2021 |
Rational drug design of indazole-based diarylurea derivatives as anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer-Aided Design; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Indazoles; Molecular Docking Simulation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib; Structure-Activity Relationship; Urea | 2017 |
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2017 |
A novel individual-cell-based mathematical model based on multicellular tumour spheroids for evaluating doxorubicin-related delivery in avascular regions.
Topics: Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dibenzocycloheptenes; Doxorubicin; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Male; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasms; Quinolines; Spheroids, Cellular; Tumor Cells, Cultured | 2017 |
New imidoyl-indazole platinum (II) complexes as potential anticancer agents: Synthesis, evaluation of cytotoxicity, cell death and experimental-theoretical DNA interaction studies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Chlorocebus aethiops; DNA, Neoplasm; HeLa Cells; HL-60 Cells; Humans; Indazoles; Neoplasms; Organoplatinum Compounds; Vero Cells | 2017 |
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
Topics: Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Humans; Indazoles; Neoplasm Proteins; Neoplasms; Phosphoproteins; Pyrimidines; Signal Transduction; Sulfonamides | 2018 |
Sulfocoumarin-, Coumarin-, 4-Sulfamoylphenyl-Bearing Indazole-3-carboxamide Hybrids: Synthesis and Selective Inhibition of Tumor-Associated Carbonic Anhydrase Isozymes IX and XII.
Topics: Amides; Binding Sites; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Catalytic Domain; Coumarins; Humans; Indazoles; Inhibitory Concentration 50; Isoenzymes; Molecular Dynamics Simulation; Neoplasms; Structure-Activity Relationship | 2017 |
Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs.
Topics: A549 Cells; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Chromatin; Endoribonucleases; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Knockdown Techniques; Humans; Indazoles; MAP Kinase Signaling System; Neoplasms; Phosphorylation; Piperazines; Promoter Regions, Genetic; Protein Transport; ras Proteins; Signal Transduction | 2017 |
USP7 small-molecule inhibitors interfere with ubiquitin binding.
Topics: Aminopyridines; Animals; Binding, Competitive; Cell Line, Tumor; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, SCID; Models, Molecular; Neoplasms; Phenols; Protein Binding; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins c-pim-1; Pyridines; Substrate Specificity; Tumor Suppressor Protein p53; Ubiquitin; Ubiquitin-Specific Peptidase 7 | 2017 |
Development of a method to determine axitinib, lapatinib and afatinib in plasma by micellar liquid chromatography and validation by the European Medicines Agency guidelines.
Topics: Afatinib; Antineoplastic Agents; Axitinib; Chromatography, Liquid; Drug Stability; Humans; Imidazoles; Indazoles; Lapatinib; Limit of Detection; Linear Models; Micelles; Neoplasms; Quinazolines; Reproducibility of Results | 2018 |
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dihydroorotate Dehydrogenase; Enzyme Inhibitors; Humans; Indazoles; Neoplasms; Oxidoreductases Acting on CH-CH Group Donors; Proteolysis; Tumor Suppressor Protein p53 | 2018 |
Solubility and bioavailability improvement of pazopanib hydrochloride.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biological Availability; Drug Liberation; Excipients; Female; Humans; Indazoles; Male; Middle Aged; Neoplasms; Polyethylene Glycols; Polyvinyls; Pyrimidines; Solubility; Sulfonamides | 2018 |
4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Humans; Indazoles; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, Inbred BALB C; Neoplasms; Structure-Activity Relationship; Tryptophan Oxygenase | 2019 |
SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait.
Topics: Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Fatty Acids; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Kaplan-Meier Estimate; Melanoma; Neoplasm Proteins; Neoplasms; Piperazines; Prognosis; Proto-Oncogene Proteins B-raf; RNA Interference; RNA Polymerase II; RNA, Small Interfering; Skin Neoplasms; Sterol Regulatory Element Binding Protein 1; Transcription, Genetic; Vemurafenib | 2019 |
Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Activation; Epirubicin; Female; Humans; Indazoles; Liposomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
[18F]-FLT positron emission tomography can be used to image the response of sensitive tumors to PI3-kinase inhibition with the novel agent GDC-0941.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dideoxynucleosides; Disease Models, Animal; Female; HCT116 Cells; Humans; Indazoles; Mice; Neoplasm Metastasis; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Signal Transduction; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.
Topics: Antigens, CD; Apoptosis; Axitinib; CD8-Positive T-Lymphocytes; Female; G2 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Immunosuppressive Agents; Indazoles; Jurkat Cells; M Phase Cell Cycle Checkpoints; Male; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR7; Receptors, CXCR3 | 2013 |
Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1.
Topics: Animals; Benzofurans; Carbon Isotopes; Fungal Proteins; Humans; Indazoles; Mice; Mitogen-Activated Protein Kinases; Neoplasms; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals | 2013 |
PARP inhibitors: pitfalls and promises.
Topics: BRCA1 Protein; BRCA2 Protein; Female; Humans; Indazoles; Male; Mutation; Neoplasm Recurrence, Local; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2013 |
ERK pathway inhibitors: how low should we go?
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Neoplasms; Oximes; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Vemurafenib | 2013 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Phenylurea Compounds; Population; Receptor Protein-Tyrosine Kinases; Sex Characteristics; Young Adult | 2014 |
Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice.
Topics: Angiogenesis Inhibitors; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Indazoles; Limit of Detection; Liquid-Liquid Extraction; Neoplasms; Pyrimidines; Spectrophotometry, Ultraviolet; Sulfonamides | 2015 |
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor ag
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Survival; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Female; HCT116 Cells; Humans; Indazoles; Indoles; Male; MCF-7 Cells; Mice, Nude; Mice, SCID; Models, Chemical; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2015 |
Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Chick Embryo; Combined Modality Therapy; Cymenes; Disease Models, Animal; Doxorubicin; Drug Synergism; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Organometallic Compounds; Oxygen Consumption; Photochemotherapy; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tumor Burden | 2015 |
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Topics: Animals; BRCA1 Protein; BRCA2 Protein; Drug Discovery; Enzyme Inhibitors; Homologous Recombination; Humans; Indazoles; Models, Molecular; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2015 |
Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.
Topics: Antineoplastic Agents; Aurora Kinase A; Cell Line, Tumor; Cell Proliferation; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship | 2015 |
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Topics: Animals; Bacterial Infections; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Escherichia coli; Heat-Shock Proteins; Humans; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Polynucleotide 5'-Hydroxyl-Kinase; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Virus Diseases | 2015 |
Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.
Topics: Angiogenesis Inhibitors; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Gene Deletion; Humans; Indazoles; Indoles; Lapatinib; Membrane Proteins; Neoplasms; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Sulfonamides; Sunitinib | 2015 |
Targeted inhibition of fascin function blocks tumour invasion and metastatic colonization.
Topics: Actins; Animals; Carrier Proteins; Cell Movement; Drug Evaluation, Preclinical; Female; High-Throughput Screening Assays; Humans; Indazoles; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Microfilament Proteins; Neoplasms; Pseudopodia | 2015 |
Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids.
Topics: Animals; Apoptosis; Cell Survival; Diazooxonorleucine; Drug Synergism; Fatty Acid Synthases; Fatty Acids; Fibroblasts; Gene Expression Regulation, Neoplastic; Glutaminase; Glycolysis; Hexokinase; Humans; Indazoles; Lactones; Metabolic Networks and Pathways; Mice; Neoplasms; Orlistat | 2015 |
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome | 2015 |
Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hyaluronic Acid; Indazoles; Lipids; Liposomes; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Paclitaxel; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Vitamin E | 2015 |
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Female; Genetic Predisposition to Disease; Heterozygote; HLA-B Antigens; Humans; Indazoles; Liver Function Tests; Male; Middle Aged; Models, Molecular; Molecular Conformation; Neoplasms; Pyrimidines; Structure-Activity Relationship; Sulfonamides; Young Adult | 2016 |
Synthesis of cinnolines via Rh(iii)-catalysed dehydrogenative C-H/N-H functionalization: aggregation induced emission and cell imaging.
Topics: Alkynes; Catalysis; Cell Line, Tumor; Cell Survival; Fluorescence; Heterocyclic Compounds, 2-Ring; Humans; Hydrogenation; Indazoles; Models, Molecular; Molecular Imaging; Molecular Structure; Neoplasms; Organometallic Compounds; Phthalazines; Rhodium | 2016 |
Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Autophagy; Binding Sites; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Female; Humans; Indazoles; Inhibitory Concentration 50; Mice; Mice, Nude; Microscopy, Fluorescence; Molecular Chaperones; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptor, ErbB-4; RNA, Small Interfering; Sildenafil Citrate; Sulfonamides; Xenograft Model Antitumor Assays | 2016 |
Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer.
Topics: Animals; Axitinib; beta Catenin; Cell Division; DNA Helicases; Glycogen Synthase Kinase 3 beta; HCT116 Cells; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Inbred C57BL; Neoplasms; Protein Kinase Inhibitors; Regeneration; Ubiquitin-Protein Ligases; Wnt Signaling Pathway; Zebrafish | 2016 |
Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Humans; Indazoles; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides | 2017 |
Topics: Adult; Aged; Aged, 80 and over; Axitinib; Dideoxynucleosides; Drug Administration Schedule; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2016 |
The multi-target drug BAI induces apoptosis in various human cancer cells through modulation of Bcl-xL protein.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytochromes c; Down-Regulation; HCT116 Cells; Humans; Indazoles; Membrane Potential, Mitochondrial; Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Thiazolidines; Tumor Suppressor Protein p53 | 2016 |
Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer.
Topics: Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Female; Folic Acid; Haptens; Humans; Imidazoles; Immunotherapy; Indazoles; Mice; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; T-Lymphocyte Subsets; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
Topics: Animals; Cells, Cultured; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Indazoles; Isoenzymes; Mice; Models, Molecular; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2008 |
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .
Topics: Administration, Oral; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides | 2008 |
Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.
Topics: Antineoplastic Agents; Biomarkers; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; DNA Adducts; Dose-Response Relationship, Drug; Half-Life; Humans; Indazoles; Infusions, Intravenous; Leukocytes; Metabolic Clearance Rate; Neoplasms; Organometallic Compounds; Ruthenium Compounds; Serum Albumin; Transferrin | 2009 |
Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.
Topics: Animals; Cell Hypoxia; Furans; HeLa Cells; Humans; Hypoxia-Inducible Factor 1; Indazoles; Mice; Mice, SCID; Neoplasms; Oxygen Consumption; Radiation Tolerance; Radiation-Protective Agents; Radiation-Sensitizing Agents; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
Topics: Acrylates; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Enalapril; Humans; Imidazoles; Indazoles; Lisinopril; Male; Mice; Mice, SCID; Neoplasms; Nifedipine; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Ramipril; Rats; Rats, Sprague-Dawley; Telmisartan; Thiophenes; Xenograft Model Antitumor Assays | 2009 |
Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response.
Topics: Axitinib; Basement Membrane; Cell Line, Tumor; Combined Modality Therapy; Dose Fractionation, Radiation; Humans; Imidazoles; Indazoles; Male; Neoplasms; Pericytes; Protein Kinase Inhibitors | 2009 |
Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Topics: Administration, Oral; Amides; Animals; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Discovery; Drug Stability; Enzyme Inhibitors; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Inhibitory Concentration 50; Mutation; Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Rats | 2009 |
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.
Topics: Algorithms; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Humans; Imidazoles; Indazoles; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Substrate Specificity; Sulfonamides; Triazines | 2010 |
Effect of pazopanib on tumor microenvironment and liposome delivery.
Topics: Angiogenesis Inhibitors; Animals; Cell Hypoxia; Doxorubicin; Drug Delivery Systems; Extracellular Fluid; Humans; Indazoles; Liposomes; Mice; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Pressure; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Tissue Distribution; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Bar the windows but open the door to randomization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Humans; Indazoles; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Sulfonamides; Treatment Outcome | 2010 |
Targeting a common collaborator in cancer development.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Doxorubicin; Drug Synergism; Humans; Indazoles; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides | 2010 |
KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Diamines; DNA-Binding Proteins; Drug Delivery Systems; Heat Shock Transcription Factors; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Indazoles; Mice; Mice, Nude; Molecular Chaperones; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms; Poly(ADP-ribose) Polymerases; Positive Transcriptional Elongation Factor B; Promoter Regions, Genetic; Transcription Factors | 2011 |
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Blood Pressure; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasms; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2011 |
YC-1 rescues cancer cachexia by affecting lipolysis and adipogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Antineoplastic Agents; Cachexia; Enzyme Activators; Female; Indazoles; Lipolysis; Mice; Mice, Inbred BALB C; Neoplasms; Signal Transduction; Tumor Necrosis Factor-alpha | 2011 |
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.
Topics: Animals; Antineoplastic Agents; Dimethyl Sulfoxide; Drug Delivery Systems; Drug Design; Humans; Indazoles; Neoplasms; Organometallic Compounds; Ruthenium Compounds | 2011 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
Topics: Animals; Antineoplastic Agents; Binding Sites; Blood Pressure; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Male; Mice; Mice, Nude; Models, Molecular; Neoplasms; Phosphorylation; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Fibroblast Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; Paclitaxel; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Biological Transport; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Phosphorylation; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2012 |
Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.
Topics: Cell Line, Tumor; Cell Movement; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Cluster Analysis; Enzyme Activation; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Gene Silencing; Humans; Indazoles; Mutation; Neoplasms; Phenotype; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Interaction Domains and Motifs; RNA Interference; Signal Transduction; Sulfonamides | 2012 |
Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Enzyme Inhibitors; Female; Humans; Indazoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Oncogene Protein v-akt; Phosphoinositide-3 Kinase Inhibitors; Protein Isoforms; PTEN Phosphohydrolase; Sulfonamides; Tumor Burden | 2012 |
Osmium(IV) complexes with 1H- and 2H-indazoles: tautomer identity versus spectroscopic properties and antiproliferative activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coordination Complexes; Dose-Response Relationship, Drug; Humans; Indazoles; Isomerism; Magnetic Resonance Spectroscopy; Mice; Mice, SCID; Neoplasms; Osmium; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Infrared; Tumor Burden; X-Ray Diffraction; Xenograft Model Antitumor Assays | 2012 |
Decade of molecular targeted therapy: abdominal manifestations of drug toxicities--what radiologists should know.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Chemical and Drug Induced Liver Injury; Cholecystitis; Early Diagnosis; Edema; Fatty Liver; Female; Health Knowledge, Attitudes, Practice; Humans; Indazoles; Infections; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Pancreatitis; Protein-Tyrosine Kinases; Pyrimidines; Radiography, Abdominal; Sulfonamides; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer.
Topics: Alanine Transaminase; Anticholesteremic Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Interactions; Humans; Hypercholesterolemia; Incidence; Indazoles; Neoplasm Proteins; Neoplasms; Polymorphism, Single Nucleotide; Pyrimidines; Reference Values; Simvastatin; Sulfonamides | 2012 |
Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
Topics: Amino Acid Sequence; Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; HEK293 Cells; Humans; Indazoles; Mechanistic Target of Rapamycin Complex 2; Mice; Molecular Sequence Data; Multiprotein Complexes; Mutation; Neoplasms; Phosphatidylinositol Phosphates; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Recombinant Proteins; Ribosomal Protein S6 Kinases; Serine; TOR Serine-Threonine Kinases | 2012 |
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
Topics: Angiogenesis Inhibitors; Animals; Anthraquinones; Antineoplastic Agents; Axitinib; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Hydralazine; Imidazoles; Indazoles; Male; Mice; Mice, Nude; Mice, SCID; NAD(P)H Dehydrogenase (Quinone); Neoplasms; Neovascularization, Pathologic; Rats; Regional Blood Flow; Vasodilator Agents; Xenograft Model Antitumor Assays | 2013 |
Is HIF-1 alpha a valid therapeutic target?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Disease Models, Animal; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Neoplasms; Neovascularization, Pathologic; Repressor Proteins; Trans-Activators; Transcription Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Culture Media, Conditioned; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; G(M1) Ganglioside; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indazoles; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lymphokines; Male; Mice; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Neuroblastoma; Platelet Endothelial Cell Adhesion Molecule-1; Precipitin Tests; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Transcription Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole] inhibits endothelial cell functions induced by angiogenic factors in vitro and angiogenesis in vivo models.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Blotting, Western; Cell Movement; Cell Proliferation; Endothelial Cells; Endothelium, Vascular; Enzyme Activators; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Guanylate Cyclase; Humans; Indazoles; Longevity; Microtubules; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Protein Kinase C; Signal Transduction; Tetrazolium Salts; Thiazoles; Thymidine; Vascular Endothelial Growth Factor A | 2005 |
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Progression; Humans; Indazoles; Indoles; Mice; Mice, SCID; Models, Molecular; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Sensitivity and Specificity; Substrate Specificity | 2005 |
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?
Topics: Administration, Oral; Angiogenesis Inhibitors; Axitinib; Biomarkers, Tumor; Clinical Trials as Topic; Diagnostic Imaging; Drug Design; Drugs, Investigational; Humans; Imidazoles; Indazoles; Neoplasms; Neovascularization, Pathologic | 2005 |
New drugs target hypoxia response in tumors.
Topics: Animals; Antineoplastic Agents; Clinical Trials, Phase I as Topic; DNA-Binding Proteins; Drugs, Investigational; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mustard Compounds; Neoplasms; Neovascularization, Pathologic; Nuclear Proteins; Phenylpropionates; Topotecan; Transcription Factors; Transplantation, Heterologous | 2005 |
RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors.
Topics: Antineoplastic Agents; Casein Kinase I; Cell Death; Genetic Testing; Humans; Indazoles; Indoles; Isoenzymes; Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction | 2006 |
Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient.
Topics: Albumins; Antineoplastic Agents; Chromatography, High Pressure Liquid; Electrophoresis, Capillary; Humans; Indazoles; Neoplasms; Organometallic Compounds; Protein Binding; Ruthenium; Ruthenium Compounds; Spectrometry, Mass, Electrospray Ionization; Transferrin | 2005 |
Synthesis and biological evaluation of 5-arylamino-6-chloro-1H-indazole-4,7-diones as inhibitors of protein kinase B/Akt.
Topics: Amination; Animals; Antineoplastic Agents; Catalysis; Cell Line, Tumor; Chlorine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indazoles; Mice; Mice, Nude; Molecular Structure; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2006 |
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
Topics: Actins; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Axitinib; Basement Membrane; Blood Vessels; Carcinoma, Lewis Lung; Collagen Type IV; Endothelium, Vascular; Imidazoles; Indazoles; Insulinoma; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Organic Chemicals; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 4.
Topics: Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Biomedical Research; CA-125 Antigen; Clinical Trials as Topic; Dasatinib; Female; Humans; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Ovarian Neoplasms; Pyrimidines; Snake Venoms; Sulfonamides; Thiazoles; Treatment Outcome | 2007 |
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cell Line, Tumor; Cyclophosphamide; Gene Expression Regulation, Neoplastic; Imidazoles; Indazoles; Liver; Mice; Mice, Inbred ICR; Neoplasms; Rats; Thrombospondin 1; Xenograft Model Antitumor Assays | 2008 |
Synthesis and antiproliferative activity of 3-amino-N-phenyl-1H-indazole-1-carboxamides.
Topics: Amides; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Humans; Indazoles; Molecular Structure; Neoplasms; Retinoblastoma Protein; Structure-Activity Relationship | 2009 |
Effects of Lonidamine on murine and human tumor cells in vitro. A morphological and biochemical study.
Topics: Animals; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Indazoles; Lactates; Lactic Acid; Leukemia, Experimental; Male; Mice; Mice, Inbred Strains; Microscopy, Electron; Microscopy, Electron, Scanning; Mitochondria; Neoplasms; Pyrazoles; Rats; Rats, Inbred Strains; Time Factors | 1984 |
Pharmacokinetics of Lonidamine after oral administration in cancer patients.
Topics: Absorption; Administration, Oral; Adult; Aged; Female; Half-Life; Humans; Indazoles; Kinetics; Male; Middle Aged; Neoplasms; Pyrazoles; Time Factors | 1984 |
Phase I toxicologic study of Lonidamine in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Indazoles; Male; Middle Aged; Neoplasms; Pyrazoles | 1984 |
Phase I and clinical pharmacologic evaluation of Lonidamine in patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Hematopoiesis; Humans; Indazoles; Male; Middle Aged; Muscles; Neoplasms; Pyrazoles; Testis | 1984 |
Phase II study of Lonidamine in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Digestive System; Drug Evaluation; Female; Humans; Indazoles; Male; Middle Aged; Muscles; Neoplasms; Pyrazoles; Time Factors | 1984 |
Phase II evaluation of Lonidamine in patients with advanced malignancy.
Topics: Adult; Aged; Antineoplastic Agents; Auditory Perception; Digestive System; Drug Evaluation; Female; Humans; Indazoles; Lactates; Lactic Acid; Male; Middle Aged; Muscles; Neoplasms; Pyrazoles; Testosterone; Time Factors | 1984 |
Early observations on the administration of Lonidamine in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Digestive System; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Muscles; Neoplasms; Pyrazoles | 1984 |
Morphological damage induced in vivo by Lonidamine on human metastatic cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Humans; Hyperthermia, Induced; Indazoles; Melanoma; Mice; Neoplasms; Pyrazoles; Skin Neoplasms | 1984 |
The cytotoxicity of N-substituted indazolones in murine and human tumor cells.
Topics: Animals; Antineoplastic Agents; Biological Availability; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Indazoles; Leukemia L1210; Mice; Neoplasms; Neoplasms, Experimental; Nucleic Acid Denaturation; Tumor Cells, Cultured | 1993 |
The effect of lonidamine (LND) on radiation and thermal responses of human and rodent cell lines.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Transformed; Cell Survival; Cricetinae; Fibroblasts; Glioma; Humans; Hyperthermia, Induced; Indazoles; Melanoma; Mice; Neoplasms; Radiotherapy; Tumor Cells, Cultured | 1991 |
Lonidamine: an innovative therapy in oncology.
Topics: Antineoplastic Agents; Humans; Indazoles; Neoplasms | 1991 |
A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Tolerance; Female; Granisetron; Humans; Indazoles; Male; Middle Aged; Nausea; Neoplasms; Pyrazoles; Serotonin Antagonists; Vomiting | 1989 |
Potentiation of radiation effects on multicellular tumor spheroids (MTS) of HeLa cells by lonidamine.
Topics: Cell Aggregation; DNA Repair; HeLa Cells; Humans; Indazoles; Models, Biological; Neoplasms; Pyrazoles; Radiation-Sensitizing Agents | 1989 |
Phase I trial of lonidamine with whole body hyperthermia in advanced cancer.
Topics: Adult; Antineoplastic Agents; Blood Cell Count; Combined Modality Therapy; Drug Evaluation; Female; Humans; Hyperthermia, Induced; Indazoles; Male; Middle Aged; Neoplasms; Pyrazoles | 1988 |
The role of mitochondrial hexokinase in neoplastic phenotype and its sensitivity to lonidamine.
Topics: Antineoplastic Agents; Hexokinase; Humans; Indazoles; Mitochondria; Neoplasms; Pyrazoles | 1988 |